



OPEN

# Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy

Giulia Giordano<sup>1✉</sup>, Marta Colaneri<sup>2</sup>, Alessandro Di Filippo<sup>2</sup>, Franco Blanchini<sup>3</sup>, Paolo Bolzern<sup>4</sup>, Giuseppe De Nicolao<sup>5</sup>, Paolo Sacchi<sup>2</sup>, Patrizio Colaneri<sup>4,6,8</sup> and Raffaele Bruno<sup>2,7,8</sup>

**Despite progress in clinical care for patients with coronavirus disease 2019 (COVID-19)<sup>1</sup>, population-wide interventions are still crucial to manage the pandemic, which has been aggravated by the emergence of new, highly transmissible variants. In this study, we combined the SIDARTHE model<sup>2</sup>, which predicts the spread of SARS-CoV-2 infections, with a new data-based model that projects new cases onto casualties and healthcare system costs. Based on the Italian case study, we outline several scenarios: mass vaccination campaigns with different paces, different transmission rates due to new variants and different enforced countermeasures, including the alternation of opening and closure phases. Our results demonstrate that non-pharmaceutical interventions (NPIs) have a higher effect on the epidemic evolution than vaccination alone, advocating for the need to keep NPIs in place during the first phase of the vaccination campaign. Our model predicts that, from April 2021 to January 2022, in a scenario with no vaccine rollout and weak NPIs ( $\mathcal{R}_0 = 1.27$ ), as many as 298,000 deaths associated with COVID-19 could occur. However, fast vaccination rollouts could reduce mortality to as few as 51,000 deaths. Implementation of restrictive NPIs ( $\mathcal{R}_0 = 0.9$ ) could reduce COVID-19 deaths to 30,000 without vaccinating the population and to 18,000 with a fast rollout of vaccines. We also show that, if intermittent open-close strategies are adopted, implementing a closing phase first could reduce deaths (from 47,000 to 27,000 with slow vaccine rollout) and healthcare system costs, without substantive aggravation of socioeconomic losses.**

Since the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome was sequenced<sup>3</sup>, researchers have rushed to develop vaccines to curb the spread of COVID-19 (refs. 4,5). Given the infeasibility of long-term lockdowns<sup>6,7</sup> and of effective contact tracing at high case numbers, as well as the availability of several approved COVID-19 vaccines, many countries have invested in mass vaccination rollouts. As of 13 March 2021, four vaccines—Pfizer/BioNTech, Moderna, Oxford–AstraZeneca AZD1222 and J&J Ad26.COV2.S—have been approved by the European Medicines Agency and the Italian Medicines Agency. The reported efficacy rates are 94% and 95%, respectively, for the Moderna and Pfizer/BioNTech vaccines<sup>8,9</sup>, up to 81.3% for AZD1222 after the second dose with a longer prime–boost interval<sup>10</sup> and up to 85% in

preventing severe disease for J&J Ad26.COV2.S 28 d after vaccination<sup>11</sup>. All vaccines have been reported to have favorable safety profiles<sup>8,9,11–14</sup>. Italy's vaccination program started in late December 2020<sup>15,16</sup> and prioritized healthcare workers, nursing home residents and people over 80 years of age<sup>17,18</sup>. As of 26 March 2021, 2,787,749 people have been vaccinated in Italy with both doses (8,765,085 doses have been administered in total)<sup>19</sup>.

Multi-pronged countermeasures, including distancing, testing and tracing, are necessary to achieve a sustained reduction in infection cases<sup>20</sup>, even more so in light of the recent emergence of new SARS-CoV-2 variants<sup>21</sup>, such as B.1.1.7 and B.1.351, which are reported to have increased transmissibility<sup>22,23</sup> and possibly cause more severe disease<sup>24</sup> compared to the original strain. Vaccination alone is not expected to be able to control the spread of the infection, and a carefully planned vaccination campaign<sup>25,26</sup> needs to be coordinated with continued implementation of NPIs<sup>27</sup> until sufficient coverage is reached to make the case fatality rate (CFR) similar to that of seasonal influenza. Table 1 outlines the main findings and implications for policy of our study.

With vaccines and variants as potential game-changers, new models to forecast epidemic scenarios and assess the associated healthcare costs are essential. Our proposed integrated model (Fig. 1a) uses the compartmental model SIDARTHE<sup>2</sup> (which we have extended here to include the effects of vaccination and now termed SIDARTHE-V) to provide the predicted evolution of new positive cases; based on new positive cases, a new data-based dynamic model derived from Italian field data computes the time profile of the resulting healthcare system costs, including hospital and intensive care unit (ICU) occupancy and deaths. Although age classes are not explicitly included in our compartmental model, they are accounted for by the data-driven model. To capture the progressive vaccination in reverse age order, the model takes into account age-dependent aggravation and death probability (Extended Data Fig. 5). Details are provided in the Methods.

We compare different scenarios to assess the effect of mass vaccination campaigns with different paces, in the presence of varying profiles of the reproduction number  $\mathcal{R}_0$  over time, due to specific SARS-CoV-2 variants and/or restrictions. We consider four effective vaccination schedules (Extended Data Fig. 4), obtained by modulating linearly the speed of the four phases, T1–T4, of Italy's vaccination plan<sup>28</sup> and yielding a different fraction of immunized people

<sup>1</sup>Department of Industrial Engineering, University of Trento, Trento, Italy. <sup>2</sup>Division of Infectious Diseases I, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. <sup>3</sup>Dipartimento di Scienze Matematiche, Informatiche e Fisiche, University of Udine, Udine, Italy. <sup>4</sup>Dipartimento di Elettronica, Informazione e Bioingegneria, Politecnico di Milano, Milan, Italy. <sup>5</sup>Department of Electrical, Computer and Biomedical Engineering, University of Pavia, Pavia, Italy. <sup>6</sup>IEIT-CNR, Milan, Italy. <sup>7</sup>Department of Clinical, Surgical, Diagnostic, and Paediatric Sciences, University of Pavia, Pavia, Italy. <sup>8</sup>These authors contributed equally: Patrizio Colaneri, Raffaele Bruno. ✉e-mail: [giulia.giordano@unitn.it](mailto:giulia.giordano@unitn.it)

**Table 1 | Policy summary**

<b>Background</b>	The second wave of the SARS-CoV-2 pandemic has severely affected Italy with a high CFR. Two potential game-changers now affect the evolution of the epidemic: the availability of vaccines and the emergence of more transmissible virus variants. We combine our compartmental epidemiological model with a new data-based model of healthcare costs to assess the effect of the vaccination campaign on the future evolution of the epidemic, in the presence of different NPIs and SARS-CoV-2 variants of concern.
<b>Main findings and limitations</b>	Even though mass vaccination has started, NPIs remain crucial to control the epidemic, in part owing to circulation of highly transmissible variants of SARS-CoV-2. Stricter restrictions curb transmission more than faster vaccine rollout. Easing NPIs leads to a surge of infection cases, calling for new closures, thus triggering intermittent restrictions. Pre-emptive strategies (first Close, then Open at low case numbers) could drastically reduce hospitalizations and deaths, without aggravating socioeconomic costs, with respect to a delayed intervention (first Open, then Close to prevent ICU saturation). As with any modeling study, there are inherent limitations. We think that our scenarios are outlined based on reasonable assumptions, but the actual epidemic evolution will depend on the adopted measures as well as the possible emergence of other variants.
<b>Policy implications</b>	Our findings strongly advocate for the need to keep NPIs in place in the first phase of the vaccination campaign until sufficient population immunity is reached. We also show the effectiveness of pre-emptive action: given a finite horizon and Close/Open phases of fixed length, closing first could spare tens of thousands of lives and reduce healthcare costs without aggravating socioeconomic losses by comparison with opening first.


within January 2022: absent (0%), slow (47%), medium (64%) and fast (90%). We also consider five different time profiles of  $\mathcal{R}_0$ : constant  $\mathcal{R}_0 = 1.27$  (high transmission); Open–Close periodic  $\mathcal{R}_0$  with average value of 1.1, in which 1-month Openings ( $\mathcal{R}_0 = 1.27$ : leaving schools and shops open, wearing face masks and keeping physical distance) alternate with 1-month Closures ( $\mathcal{R}_0 = 0.9$ : closing schools, shops, restaurants and entertainment places), starting with an Opening phase; constant  $\mathcal{R}_0 = 1.1$ ; Close–Open periodic  $\mathcal{R}_0$  with average value of 1.1, in which 1-month Closures alternate with 1-month Openings, starting with a Closure phase; constant  $\mathcal{R}_0 = 0.9$  (eradication).

Our main findings are summarized by the deaths versus speed curves in Fig. 1b, which show mortality as a function of the vaccination rollout speed for each  $\mathcal{R}_0$  profile. Vaccination is assumed to reduce viral transmission as well as disease severity and risk of death. The different vaccination schedules could also be interpreted as different proportions of infections, diseases and deaths that the vaccine successfully stops, thus constituting a sensitivity analysis. The combination of the four vaccination schedules with the five  $\mathcal{R}_0$  profiles leads to 20 distinct scenarios (Fig. 1b). Eradication is associated with an almost constant curve; however, with  $\mathcal{R}_0 = 1.27$ , the proportion of deaths with slow, medium and fast vaccination schedules could be as small as 30%, 24% and 17% of the 298,000 deaths with no vaccination, respectively. The deaths versus speed curves are flatter when  $\mathcal{R}_0$  is kept smaller; implementation of stringent NPIs drastically reduces sensitivity to vaccination delays. Restrictive containment strategies ( $\mathcal{R}_0 = 0.9$ ) lead to a number of deaths that could be as small as 10% of deaths with weak restrictions ( $\mathcal{R}_0 = 1.27$ ): depending on the  $\mathcal{R}_0$  profile, deaths in the period from April 2021 to January 2022 vary in the range of 30,000–298,000 (no vaccination rollout), 20,000–91,000 (slow vaccination rollout), 19,000–72,000 (medium vaccination rollout) and 18,000–51,000 (fast vaccination rollout). Therefore, NPIs appear to have a stronger effect on mortality than vaccination speed. When planning mid-term interventions, pre-emption reduces mortality and healthcare system costs at no additional socioeconomic cost by comparison with delayed implementation. Both intermittent restrictions with the same average  $\mathcal{R}_0$  involve similar socioeconomic costs, but starting with a Closing phase improves on constant containment, which is better than starting with an Opening phase. For all vaccination schedules, the Close–Open strategy saves more than 14,000 lives compared to Open–Close. Hospital and ICU occupancy as a function of the vaccination speed follow a similar pattern (Extended Data Fig. 8).

Considering a medium vaccination speed, Fig. 2a–f shows the epidemic evolution for different constant values of  $\mathcal{R}_0$  (the scenarios in the absence of vaccination are in Extended Data Fig. 2). Despite vaccination and implementation of current containment measures, a higher transmissibility due to the spread of new variants would cause a dramatic surge in infection cases, leading, within 2 months, to a peak of almost 4,000 ICU beds needed and more than 700 daily deaths. To prevent this from happening and to reduce hospital occupancy and mortality,  $\mathcal{R}_0$  can be reduced through increased stringency of NPIs, particularly in the presence of highly transmissible variants.

The need to implement new restrictions is likely to trigger intermittent containment measures, with the alternation of higher- $\mathcal{R}_0$  and lower- $\mathcal{R}_0$  phases<sup>29,30</sup>. In Open–Close strategies, closures are delayed and applied only in anticipation of the pressure on the healthcare system becoming unbearable. Each intermittent Open–Close strategy can be associated with a Close–Open strategy that alternates opening and closing phases of the same duration, with the only difference of starting with a closure. Figure 2g–l compares the two different intermittent strategies, with average  $\mathcal{R}_0$  equal to 1.1, under medium-speed vaccination (the scenarios in the absence of vaccination are in Extended Data Fig. 3). Opening first (Open–Close) or closing first (Close–Open) strongly affects healthcare system costs (which depend on case numbers), whereas socioeconomic costs (which depend on the duration and stringency of restrictions) are substantially unchanged. Without aggravation of social and economic losses with respect to an Open–Close strategy, a pre-emptive Close–Open strategy drastically reduces forthcoming infection numbers (decreasing the peak of daily new cases from 38,000 to 14,000), hospital and ICU occupancy and deaths (decreasing the peak of daily deaths from 600 to 400). Even though the average  $\mathcal{R}_0$  is above 1, the effective reproduction number  $\mathcal{R}_t = \mathcal{R}_0 S(t)$  goes below 1 due to the decreasing susceptible fraction  $S(t)$ ; hence, the epidemic is eventually suppressed (Methods).

Finally, we comparatively assess the effect of mass vaccination with different paces (which could be also interpreted as the effect of different vaccine efficacy). We assume that the number of reinfections occurring within the considered horizon is negligible. Figure 3 compares the effect of slow versus fast vaccination under the intermittent Open–Close strategy. Although vaccination leads to a net reduction in deaths and hospital and ICU occupancy compared to the corresponding scenario without vaccination, the difference in effect between slow and fast vaccination is modest. The speed



**Fig. 1 | Model scheme and summary of our findings.** **a**, Graphical scheme of our model (adapted from Giordano et al.<sup>2</sup>). The compartmental SIDARTHE-V epidemiological model provides daily new cases as an input to a novel data-based model of casualties and healthcare system costs. The SIDARTHE-V model captures the dynamic interactions among nine mutually exclusive infection stages in the population: S, Susceptible (uninfected); I, Infected (asymptomatic infected, undetected); D, Diagnosed (asymptomatic infected, detected); A, Ailing (symptomatic infected, undetected); R, Recognized (symptomatic infected, detected); T, Threatened (infected with life-threatening symptoms, detected); H, Healed (recovered); E, Extinct (dead); and V, Vaccinated (successfully immunized). The SIDARTHE-V model provides the time evolution of daily new infection cases, based on which the data-driven model computes the evolution of deaths and ICU and hospital occupancy. **b**, Death versus vaccination speed curves. For a given  $\mathcal{R}_0$  profile, the curve gives the death toll in the period from April 2021 to January 2022 as a function of the average vaccination speed, measured as the fraction of vaccinated population at the end of the period. The death versus vaccination speed curves corresponding to a constant reproduction number are reported in purple ( $\mathcal{R}_0 = 1.27$ ), orange ( $\mathcal{R}_0 = 1.1$ ) and blue ( $\mathcal{R}_0 = 0.9$ ), whereas those corresponding to intermittent strategies are reported in red (Open–Close) and green (Close–Open).


of vaccination becomes more important with a higher  $\mathcal{R}_0$ , at the price of many more deaths. In Extended Data Figs. 6 and 7, we also consider an adaptive vaccination scenario, where an increase in the number of current infection cases leads to a reduction of the vaccination rate, due to the augmented strain on the healthcare system. Both mortality and healthcare system costs increase, reinforcing conclusions about the greater importance of containment measures over vaccination rates.

There are limitations to our study. The SIDARTHE-V model is a mean-field compartmental model, which relies on the assumption of a large population with homogeneous mixing and provides predictions that are averaged over the whole population; hence, geographical heterogeneity is not taken into account. More complex and detailed models, which account for spatial effects, social networks and the specificity of individual behaviors, can be developed and used to evaluate vaccination strategies<sup>31</sup>. Also, we assumed that vaccination is effective against SARS-CoV-2 variants. However, several concerns are raised regarding variants and their potential for vaccine-induced immunity escape<sup>32,33</sup>, preliminary reports suggest that some COVID-19 vaccines might retain efficacy against variants<sup>34,35</sup>, although it might be attenuated<sup>36</sup>, whereas data suggest that Oxford–AstraZeneca AZD1222 might be less effective against B.1.351 (ref. 37). In our scenarios, we also optimistically assumed that successfully vaccinated individuals gain protection against death and hospitalization starting 3 weeks after the first vaccine dose rather than after the second dose.

Vaccination started with slow rates, and priority was given to healthcare personnel, thus delaying the CFR decrease: even under the fast rollout, the CFR would not be halved before June (Extended Data Fig. 4c). Because the decrease rate of the CFR cannot be made


arbitrarily fast, due to availability and administration rate of vaccines, our findings confirm that, in the first phase of the mass vaccination campaign, NPIs are crucial, regardless of the (realistic) vaccination speed. Given the circulation of highly transmissible SARS-CoV-2 variants and the risk of potential emergence of vaccine-resistant mutations,  $\mathcal{R}_0$  must be kept low until a sufficient level of population immunity is achieved and a large enough portion of the vulnerable population has been immunized. Only then can NPIs be safely and gradually released; the time at which this happens will depend on the speed of vaccine rollout.

To outrun the faster spread of the virus variants, the United Kingdom (UK) launched an extensive COVID-19 vaccination campaign, accelerated by extending the interval between doses: more than 29 million people have received at least one vaccine dose as of 25 March, which has reduced deaths and hospital admissions<sup>38</sup>. Our model confirms that implementation of strong NPIs could bring the epidemic under control without vaccines or before reaching population immunity, as happened in the UK during January 2021: the highly transmissible B.1.1.7 variant, which first emerged in Kent, UK, and spread throughout the UK, was brought under control by lockdown restrictions kept in place during the first crucial phases of the vaccine rollout campaign. In the meantime, vaccine rollout in the UK has enabled planning subsequent gradual release of NPIs<sup>38,39</sup>. Although the UK is heading into the second phase of the vaccination campaign, Italy is at an early phase, close to the UK's first. To contain the new Italian outbreak of SARS-CoV-2, driven by the new variants of concern, it is important to maintain NPIs to prevent an uncontrolled surge in the number of infections, hospitalizations and deaths, because vaccination alone will be insufficient to control the epidemic. In parallel, accelerating the vaccination campaign, as was



**Fig. 2 | The effect of different constant values of  $\mathcal{R}_0$  and intermittent strategies.** Time evolution of the epidemic, in the presence of medium-speed vaccination (64% of the population vaccinated within January 2022), when: **a–f**, different constant values of  $\mathcal{R}_0$ , namely  $\mathcal{R}_0 = 1.27$  (purple),  $\mathcal{R}_0 = 1.1$  (orange) and  $\mathcal{R}_0 = 0.9$  (blue), are assumed, resulting from different variants and/or containment strategies, and when: **g–l**, two alternative intermittent strategies are enforced, with an average value of  $\mathcal{R}_0$  equal to 1.1. The Open–Close strategy (red) switches every month between  $\mathcal{R}_0 = 1.27$  and  $\mathcal{R}_0 = 0.9$  starting with  $\mathcal{R}_0 = 1.27$ . The Close–Open strategy (green) switches every month between  $\mathcal{R}_0 = 0.9$  and  $\mathcal{R}_0 = 1.27$  starting with  $\mathcal{R}_0 = 0.9$ . **a,g**, Time evolution of the fractions of susceptibles, vaccinated, infected and recovered, and dead. **b,h**, Daily new cases. **c,i**, Active cases. **d,j**, Hospital occupancy. **e,k**, ICU occupancy. **f,l**, Daily deaths.





**Fig. 3 | The effect of different vaccination paces.** Time evolution of the epidemic, with an intermittent Open–Close strategy enforced, in the presence of slow vaccination (47% of the population vaccinated within January 2022, red) or fast vaccination (90% of the population vaccinated within January 2022, blue). **a**, Time evolution of the fractions of susceptible, vaccinated, infected and recovered, and dead. **b**, Daily new cases. **c**, Active cases. **d**, Hospital occupancy. **e**, ICU occupancy. **f**, Daily deaths.

done in the UK (perhaps also by increasing the interval between doses), would be worth considering.

### Online content

Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41591-021-01334-5>.

Received: 15 February 2021; Accepted: 31 March 2021;

Published online: 16 April 2021

### References

- Stasi, C., Fallani, S., Voller, F. & Silvestri, C. Treatment for COVID-19: an overview. *Eur. J. Pharmacol.* **889**, 173644 (2020).
- Giordano, G. et al. Modelling the COVID-19 epidemic and implementation of population-wide interventions in Italy. *Nat. Med.* **26**, 855–860 (2020).
- Wu, F. et al. A new coronavirus associated with human respiratory disease in China. *Nature* **579**, 265–269 (2020).
- Wang, J., Peng, Y., Xu, H., Cui, Z. & Williams, R. O. The COVID-19 vaccine race: challenges and opportunities in vaccine formulation. *AAPS PharmSciTech.* **21**, 225 (2020).
- Rawat, K., Kumari, P. & Saha, L. COVID-19 vaccine: a recent update in pipeline vaccines, their design and development strategies. *Eur. J. Pharmacol.* **892**, 173751 (2021).
- Abbasi, K. Behavioural fatigue: a flawed idea central to a flawed pandemic response. *BMJ* **370**, m3093 (2020).
- Rypdal, K., Bianchi, F. M. & Rypdal, M. Intervention fatigue is the primary cause of strong secondary waves in the COVID-19 pandemic. *Int. J. Environ. Res. Public Health* **17**, 9592 (2020).
- Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *N. Engl. J. Med.* **383**, 2603–2615 (2020).
- Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N. Engl. J. Med.* **384**, 403–416 (2021).
- Voysey, M. et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. *Lancet* **397**, 881–891 (2021).
- US Food and Drug Administration. FDA Briefing Document. Janssen Ad26. COV2.S Vaccine for the Prevention of COVID-19. Vaccines and Related Biological Products Advisory Committee Meeting, February 26, 2021. <https://www.fda.gov/media/146217/download>
- Gee, J. et al. First month of COVID-19 vaccine safety monitoring—United States, December 14, 2020–January 13, 2021. *MMWR Morb. Mortal. Wkly Rep.* **70**, 283–288 (2021).
- Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *Lancet* **397**, 99–111 (2021).
- European Medicines Agency. COVID-19 Vaccine AstraZeneca: benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets. <https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-benefits-still-outweigh-risks-despite-possible-link-rare-blood-clots> (2021).
- ANSA. Pfizer vaccine arrives in Italy. [https://www.ansa.it/english/news/2020/12/30/pfizer-vaccine-arrives-in-italy\\_4690fcec-88a8-4919-b821-afc01fc3955a.html](https://www.ansa.it/english/news/2020/12/30/pfizer-vaccine-arrives-in-italy_4690fcec-88a8-4919-b821-afc01fc3955a.html) (2020).
- ANSA. First Moderna vaccine doses arrive in Italy. [https://www.ansa.it/english/news/general\\_news/2021/01/12/first-moderna-vaccine-doses-arrive-in-italy\\_ce39273f-aa51-4d55-9f8b-d5c658633007.html](https://www.ansa.it/english/news/general_news/2021/01/12/first-moderna-vaccine-doses-arrive-in-italy_ce39273f-aa51-4d55-9f8b-d5c658633007.html) (2021).
- Reuters. Italy kicks off vaccinations against COVID-19 in Rome. <https://www.reuters.com/article/health-coronavirus-italy-vaccine/italy-kicks-off-vaccinations-against-covid-19-in-rome-idUKL1N2J703O> (2021).
- Ministero della salute (Italian Ministry of Health). Vaccinazione anti-SARS-CoV-2/COVID-19: PIANO STRATEGICO: Elementi di preparazione e di implementazione della strategia vaccinale. <https://www.vaccinarsardegna.org/assets/uploads/files/378/piano-strategico-vaccinazione-anti-covid19.pdf> (2020).
- Presidenza del Consiglio dei Ministri. Ministero della Salute. Commissario Straordinario Covid-19. Report Vaccini Anti COVID-19. <https://www.governo.it/it/cscovid19/report-vaccini/> (2021).

20. Priesemann, V. et al. Calling for pan-European commitment for rapid and sustained reduction in SARS-CoV-2 infections. *Lancet* **397**, 92–93 (2021).
21. Priesemann, V. et al. An action plan for pan-European defence against new SARS-CoV-2 variants. *Lancet* **397**, 469–470 (2021).
22. Davies, N. G. et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. *Science* **372**, eabg3055 (2021).
23. Abbott, S., Funk, S. & CMMID COVID-19 Working Group. Local area reproduction numbers and S-gene target failure. <https://cmmid.github.io/topics/covid19/local-r-sgtf.html> (2021).
24. Horby, P. et al. NERVTAG note on B.1.1.7 severity. <https://www.gov.uk/government/publications/nervtag-paper-on-covid-19-variant-of-concern-b117> (2021).
25. Bubar, K. M. et al. Model-informed COVID-19 vaccine prioritization strategies by age and serostatus. *Science* **371**, 916–921 (2021).
26. Ramos A. M., Vela-Pérez, M., Ferrández, M. R., Kubik, A. B. & Ivorra, B. Modeling the impact of SARS-CoV-2 variants and vaccines on the spread of COVID-19. Preprint at ResearchGate <https://doi.org/10.13140/RG.2.2.32580.24967/2> (2021).
27. Grundel, S. et al. How to coordinate vaccination and social distancing to mitigate SARS-CoV-2 outbreaks. Preprint at *medRxiv* <https://doi.org/10.1101/2020.12.22.20248707> (2020).
28. Ministero della Salute. Vaccinazione anti-SARS-CoV-2/COVID-19, Piano Strategico, elementi di preparazione e di implementazione della strategia vaccinale. [http://www.salute.gov.it/imgs/C\\_17\\_pubblicazioni\\_2986\\_allegato.pdf](http://www.salute.gov.it/imgs/C_17_pubblicazioni_2986_allegato.pdf) (2020).
29. Kissler, S. M. et al. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. *Science* **368**, 860–868 (2020).
30. Bin, M. et al. Post-lockdown abatement of COVID-19 by fast periodic switching. *PLoS Comput. Biol.* **17**, e1008604 (2021).
31. Tetteh, J. N. A., Nguyen, V. K. & Hernandez-Vargas, E. A. COVID-19 network model to evaluate vaccine strategies towards herd immunity. Preprint at *medRxiv* <https://doi.org/10.1101/2020.12.22.20248693> (2020).
32. Starr, T. N. et al. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. *Science* **371**, 850–854 (2021).
33. Fontanet, A. et al. SARS-CoV-2 variants and ending the COVID-19 pandemic. *Lancet* **397**, 952–954 (2021).
34. Callaway, E. Could new COVID variants undermine vaccines? Labs scramble to find out. *Nature* **589**, 177–178 (2021).
35. Burki, T. Understanding variants of SARS-CoV-2. *Lancet* **397**, 462 (2021).
36. Luring, A. S. & Hodcroft, E. B. Genetic variants of SARS-CoV-2—what do they mean? *JAMA* **325**, 529–531 (2021).
37. Madhi, S. A. et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. *N. Engl. J. Med.* <https://doi.org/10.1056/NEJMoa2102214> (2021).
38. Lopez Bernal, J. et al. Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England. Preprint at *medRxiv* <https://doi.org/10.1101/2021.03.01.21252652> (2021).
39. GOV.UK. Coronavirus (COVID-19). <https://www.gov.uk/coronavirus>

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s)

## Methods

Our overall model (Fig. 1a) combines the flexibility and insight of compartmental models with the intrinsic robustness of a black-box healthcare system cost model based on observed data. The SIDARTHE-V model, including the compartment of vaccinated individuals (first block in Fig. 1a), generates the predicted evolution of new positive cases, which is used by the data-based model (second block in Fig. 1a) that captures hospitalization flows and quantifies healthcare system costs in terms of deaths and of hospital and ICU occupancy.

The data used to inform the model are taken from publicly available repositories and reports: <https://github.com/pcm-dpc/COVID-19/tree/master/dati-andamento-nazionale> for epidemiological data on the evolution of the COVID-19 epidemic in Italy until 12 March 2021; [https://www.epicentro.iss.it/coronavirus/bollettino/Bollettino-sorveglianza-integrata-COVID-19\\_13-gennaio-2021.pdf](https://www.epicentro.iss.it/coronavirus/bollettino/Bollettino-sorveglianza-integrata-COVID-19_13-gennaio-2021.pdf) for age-dependent CFRs; and <http://dati.istat.it/Index.aspx> for demographic information on the Italian population (needed to take age classes into account). Indeed, although age classes are not explicitly included in our compartmental SIDARTHE-V model, they are taken into account by the data-based model for healthcare system costs, which quantifies hospitalizations, ICU occupancy and deaths. The CFRs (and hospitalization rates) are computed by taking population age classes into account, as shown in Extended Data Fig. 5, using demographic information from <http://dati.istat.it/Index.aspx>.

**SIDARTHE-V compartmental model.** The SIDARTHE-V compartmental model shown in Fig. 1a extends the SIDARTHE model, introduced by Giordano et al.<sup>2</sup>, by including the effect of vaccination. This leads to nine possible stages of infection: susceptible individuals (S) are uninfected and not immunized; infected individuals (I) are asymptomatic and undetected; diagnosed individuals (D) are asymptomatic but detected; ailing individuals (A) are symptomatic but undetected; recognized individuals (R) are symptomatic and detected; threatened individuals (T) have acute life-threatening symptoms and are detected; healed individuals (H) have had the infection and recovered; extinct individuals (E) died because of the infection; and vaccinated individuals (V) have successfully obtained immunity without having been infected.

The dynamic interaction among these nine clusters of the population is described by the following nine ordinary differential equations, describing how the fraction of the population in each cluster evolves over time:

$$\dot{S}(t) = -S(t)(\alpha I(t) + \beta D(t) + \gamma A(t) + \delta R(t)) - \varphi(S(t)) \quad (1)$$

$$\dot{I}(t) = S(t)(\alpha I(t) + \beta D(t) + \gamma A(t) + \delta R(t)) - (\varepsilon + \zeta + \lambda) I(t) \quad (2)$$

$$\dot{D}(t) = \varepsilon I(t) - (\eta + \rho) D(t) \quad (3)$$

$$\dot{A}(t) = \zeta I(t) - (\theta + \mu + \kappa) A(t) \quad (4)$$

$$\dot{R}(t) = \eta D(t) + \theta A(t) - (\nu + \xi + \tau_1) R(t) \quad (5)$$

$$\dot{T}(t) = \mu A(t) + \nu R(t) - (\sigma + \tau_2) T(t) \quad (6)$$

$$\dot{H}(t) = \lambda I(t) + \rho D(t) + \kappa A(t) + \xi R(t) + \sigma T(t) \quad (7)$$

$$\dot{E}(t) = \tau_1 R(t) + \tau_2 T(t) \quad (8)$$

$$\dot{V}(t) = \varphi(S(t)) \quad (9)$$

The uppercase Latin letters (state variables) represent the fraction of population in each stage, whereas all the considered parameters, denoted by Greek letters, are positive numbers and have the following meaning:

- The contagion parameters  $\alpha$ ,  $\beta$ ,  $\gamma$  and  $\delta$ , respectively, denote the transmission rate (defined as the probability of disease transmission in a single contact multiplied by the average number of contacts per person) due to contacts between a Susceptible individual and an Infected, a Diagnosed, an Ailing or a Recognized individual. These parameters can be modified by social distancing policies (for example, closing schools, remote working and lockdown) as well as physical distancing, adoption of proper hygiene behaviors and use of personal protective equipment. The risk of contagion due to Threatened individuals, treated in proper ICUs, is assumed to be negligible.
- The diagnosis parameters  $\varepsilon$  and  $\theta$ , respectively, denote the probability rate of detection, relative to asymptomatic and symptomatic cases. These parameters, also modifiable, reflect the level of attention on the disease and the number of tests performed over the population: they can be increased by enforcing a massive contact tracing and testing campaign.

- The symptom onset parameters  $\zeta$  and  $\eta$  represent the probability rate at which an infected individual, respectively, undetected and detected, develops clinically relevant symptoms. Although disease dependent, they might be partially reduced by improved therapies and acquisition of immunity against the virus.
- The critical/aggravation parameters  $\mu$  and  $\nu$ , respectively, denote the rate at which undetected and detected infected symptomatic individuals develop life-threatening symptoms. The parameters can be reduced by means of improved therapies and acquisition of immunity against the virus.
- The mortality parameters  $\tau_1$  and  $\tau_2$ , respectively, denote the mortality rate for infected individuals with symptoms (presumably in hospital wards) and with acute symptoms (presumably in ICUs) and can be reduced by means of improved therapies.
- The healing parameters  $\lambda$ ,  $\kappa$ ,  $\xi$ ,  $\rho$  and  $\sigma$  denote the rate of recovery for the five classes of infected individuals and can be increased thanks to improved treatments and acquisition of immunity against the virus.
- The vaccination function  $\varphi(S(t))$  represents the rate at which susceptible individuals successfully achieve immunity through vaccination (the rate depends on both the actual vaccination rate and the vaccine efficacy); possible choices are the state-dependent  $\varphi(S(t)) = \varphi S(t)$ , leading to an exponential decay of the number of susceptible individuals, and  $\varphi(S(t)) = \varphi S(t) > 0$  as long as  $S(t) > 0$  ( $\varphi(S(t)) = 0$  otherwise), leading to a linear decay. In the latter case,  $\varphi(t)$  can be piecewise constant, as in the vaccination profiles in Extended Data Fig. 4. It is worth stressing that any vaccine (Pfizer/BioNTech, Moderna, Oxford–AstraZeneca, J&J and any other) can be considered within the model as the inducer of immunity, without altering the model validity.

Concerning the duration of immunity, correlates of protection against SARS-CoV-2 infection in humans are not yet established, but the results of a clinical trial with the mRNA-1273 vaccine show that, despite a slight expected decline in titers of binding and neutralizing antibodies, mRNA-1273 has the potential to provide durable humoral immunity: as the natural infection, which produces variable antibody longevity and might induce robust memory B cell responses, also mRNA-1273 vaccine elicited primary CD4 type 1 helper T responses 43 d after the first vaccination, and protection persists after 119 d<sup>40</sup>. Although it is unclear how long protective effects last beyond the first few months after vaccination, some studies suggest that the elicited neutralizing activity is maintained for up to 8 months after the natural infection with SARS-CoV-2 (refs.<sup>41,42</sup>). Reasonably, considering that a similar pattern of responses lasting over time will also emerge after vaccinations, it would be at least unlikely that any potential reinfection would occur over the horizon considered by our scenarios. This is why reinfections have not been explicitly considered in the model, given that we are focused on short-term horizons.

Also, it is worth stressing that we are considering the rate of successful immunization, not of vaccine dose administration (this is why immunity is built up with a slower pace with respect to the expected vaccine roll-out logistics); people who get vaccinated, but for whom the vaccine is not effective, remain susceptible and are, therefore, equally at risk of serious disease and death.

The system is compartmental and has the mass conservation property: as it can be immediately checked,  $\dot{S}(t) + \dot{I}(t) + \dot{D}(t) + \dot{A}(t) + \dot{R}(t) + \dot{H}(t) + \dot{E}(t) + \dot{V}(t) = 0$ , hence the sum of the states (total population) is constant. Because the variables denote population fractions, we have:

$$S(t) + I(t) + D(t) + A(t) + R(t) + T(t) + H(t) + E(t) + V(t) = 1,$$

where 1 denotes the total population, including deceased. Note that  $H(t)$ ,  $E(t)$  and  $V(t)$  are cumulative variables that depend only on the other ones and on their own initial conditions.

Given an initial condition  $S(0)$ ,  $I(0)$ ,  $D(0)$ ,  $A(0)$ ,  $R(0)$ ,  $T(0)$ ,  $H(0)$ ,  $E(0)$  and  $V(0)$  summing up to 1, if the vaccination function  $\varphi(S(t)) > 0$  as long as  $S(t) > 0$ , the variables converge to

$$\bar{S} = 0, \bar{I} = 0, \bar{D} = 0, \bar{A} = 0, \bar{R} = 0, \bar{T} = 0, \bar{H} \geq 0, \bar{E} \geq 0, \bar{V} \geq 0,$$

with  $\bar{H} + \bar{E} + \bar{V} = 1$ . So only the vaccinated/immunized, the healed and the deceased populations are eventually present, meaning that the epidemic phenomenon is over. All the possible equilibria are given by  $(0, 0, 0, 0, 0, 0, \bar{H}, \bar{E}, \bar{V})$ , with  $\bar{H} + \bar{E} + \bar{V} = 1$ .

To better understand the system behavior, we partition it into three subsystems: the first includes just variable  $S$  (corresponding to susceptible individuals); the second, which we denote as the *IDART* subsystem, includes  $I$ ,  $D$ ,  $A$ ,  $R$  and  $T$  (the infected individuals); and the third includes variables  $H$ ,  $E$  and  $V$  (representing healed, defunct and vaccinated/immunized).

The overall system can be seen as a positive linear system subject to a feedback signal  $u$ . Defining  $x = [I \ D \ A \ R \ T]^T$ , we can rewrite the *IDART* subsystem as







Recalling that  $V(t)$  is the fraction of vaccine-immunized individuals, and vaccination order follows the reverse of the age, the probability of death for an individual of age  $a$  who becomes infected at time  $t$  is

$$P(\text{Death}|\text{Age} = a, \text{Infected}, t) = \begin{cases} 0, & V(t) > P(\text{Age} > a) \\ CFR(a), & V(t) \leq P(\text{Age} > a) \end{cases}$$

Then, the time-varying CFR is obtained by the total probability theorem:

$$CFR(t) = \sum_{a=0}^{100} P(\text{Death}|\text{Age} = a, \text{Infected}, t)P(\text{Age} = a|\text{Infected}, t)$$

where  $P(\text{Age} = a|\text{Infected}, t)$  denotes the probability that the age of an individual is  $a$ , knowing that the individual became infected at time  $t$ . During the second wave, the age distribution of the infected individuals<sup>46</sup> was similar to the age distribution of the Italian population. For instance, 56% of the population is in the age range 0–50 years, 28% is in the range 51–70 years and 16% is older than 70 years. In comparison, 55.6% of diagnosed cases between 18 December 2020 and 10 January 2021 were in age range 0–50 years, 28% in the range 51–70 years and 16.4% over 70 years. Therefore,  $P(\text{Age} = a|\text{Infected}, t) = P(\text{Age} = a)$ , so that the CFR of an individual infected at time  $t$  can be computed as

$$CFR(t) = \sum_{a=0}^{100} P(\text{Death}|\text{Age} = a, \text{Infected}, t)P(\text{Age} = a)$$

The steps of the procedure for the computation of  $CFR(t)$  are summarized in Extended Data Fig. 5. The time-varying profiles  $CFR(t)$  for the three vaccination schedules are plotted in Extended Data Fig. 4. Because protection against hospitalization and death has been observed already after the first dose, the calculation of the time-varying CFR was based on first dose administration, assumed twice as fast as second dose administration.

Finally, the input–output model that accounts for the effect of vaccination is given by

$$d(t) = \sum_{i=0}^{\infty} w(i)C(t-i)n(t-i), \quad C(t) = \frac{CFR(t)}{CFR_0}$$

Due to the time-varying coefficient  $C(t)$ , the same number of new cases will yield fewer and fewer deaths as vaccination comes to protect older segments of the population.

Dynamic models for hospital and ICU occupancies were developed in a similar way. The estimated parameters and their percent coefficients of variation for hospital occupancy (estimated delay  $k = 0$ ) were:

$$a = 0.9522, \quad CV(\%) = 0.226$$

$$f = 0.0694, \quad CV(\%) = 4.26$$

Those for ICU occupancy (estimated delay  $k = 0$ ) were:

$$a = 0.953, \quad CV(\%) = 0.328$$

$$f = 0.00677, \quad CV(\%) = 6.297$$

Assuming that gravity reduction parallels the lethality one, the effect of vaccination on hospital and ICU occupancies was described by modulating the input through the time-varying coefficient  $C(t)$ .

As seen in Extended Data Fig. 9, the three data-based dynamic models provide a very good fitting of deaths and hospital and ICU occupancies.

**Our scenarios: different values of  $\mathcal{R}_0$ .** The chosen values of  $\mathcal{R}_0$  are based on plausible scenarios, in view of what has been observed throughout the past year in Italy, with a suitable combination of (1) presence of SARS-CoV-2 variants with increased transmissibility and (2) enforced restrictions. In particular, the mild restrictions that kept  $\mathcal{R}_0$  around 0.9 with the original virus strain would keep it around 1.3 (at least) if the new variants increase transmissibility of at least 40–50%, as reported in the literature<sup>49–51</sup>. In fact, values around  $\mathcal{R}_0 = 1.3$  were observed in mid-March 2021 in areas of Italy where the UK variant is becoming dominant. We have not considered even worse scenarios, because a higher  $\mathcal{R}_0$  is unlikely to be sustainable: even stricter restrictions would then be enforced to prevent it from increasing. On the other hand, we deem it unlikely that restrictions so stringent to bring  $\mathcal{R}_0$  below 0.9 would be enforced; hence, we have chosen this value as the other extreme scenario.

**Our scenarios: intermittent strategies, Open–Close and Close–Open.** In some of our scenarios, we consider intermittent strategies that rely on the alternation of Open phases (associated with a larger  $\mathcal{R}_0$ ) and Close phases (associated with a smaller  $\mathcal{R}_0$ ) with a fixed proportion.

One of our main results is that, when planning over a fixed time period and having to set the order of two phases (Open and Close) with fixed length, starting with the Close phase is always an advantage. This happens because the associated healthcare system costs depend on the total number of infection cases in the considered time period, which is much larger if the Open phase comes first; hence, starting with a Close phase drastically reduces health costs and losses. On the other hand, socioeconomic costs are proportional to the duration and stringency of the restrictions, regardless of when they are enforced; hence, intermittent closures yield similar socioeconomic costs. Given a finite horizon and Close/Open phases of fixed length, closing before opening does not bring any additional socioeconomic cost, with respect to opening before closing, because the closing (and opening) phases have the same duration in both scenarios.

This principle holds true irrespective of the initial size of the epidemic. For instance, with very low case numbers, starting with a Close phase could approach or even achieve eradication, after which reopening would be completely safe (such an eradication approach has been successfully adopted, for example, by New Zealand<sup>52,53</sup>), whereas, if starting with an Open phase, the number of infection cases would grow exponentially, and the following Close phase could only mitigate the epidemic expansion. Of course, the higher the initial case number, the more visible the difference between the two strategies.

Also, the principle (if Open and Close phases with a fixed proportion need to be alternated in a periodic fashion, then starting with a Close phase is always preferable) remains valid regardless of the phase duration. In our scenarios, we have chosen 1-month-long phases, because this is a frequently observed choice in many countries (for example, in accordance with implemented policies in Italy but also in Israel) and is a sufficiently long time for the effect of interventions to be well visible.

**Reporting Summary.** Further information on research design is available in the Nature Research Reporting Summary linked to this article.

### Data availability

We gathered all epidemiological and demographic data from publicly available sources: <https://github.com/pcm-dpc/COVID-19/tree/master/dati-andamento-nazionale>, [https://www.epicentro.iss.it/coronavirus/bollettino/Bollettino-sorveglianza-integrata-COVID-19\\_13-gennaio-2021.pdf](https://www.epicentro.iss.it/coronavirus/bollettino/Bollettino-sorveglianza-integrata-COVID-19_13-gennaio-2021.pdf) and <http://dati.istat.it/Index.aspx>. Data are also included in Extended Data Figs. 1 and 9 and in the code folder: <https://giuliagiordano.dii.unitn.it/docs/papers/VaccineVariantsCode.zip>.

### Code availability

The codes are available at <https://giuliagiordano.dii.unitn.it/docs/papers/VaccineVariantsCode.zip>.

### References

- Widge, A. T. et al. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. *N. Engl. J. Med.* **384**, 80–82 (2021).
- Robbiani, D. F. et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. *Nature* **584**, 437–442 (2020).
- Dan, J. M. et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. *Science* **371**, eabf4063 (2021).
- D'Arienzo, M. & Coniglio, A. Assessment of the SARS-CoV-2 basic reproduction number,  $R_0$ , based on the early phase of COVID-19 outbreak in Italy. *Biosaf. Health* **2**, 57–59 (2020).
- MATLAB System Identification Toolbox, 9.13 (R2020b). <https://www.mathworks.com/products/sysid.html>
- Italian Ministry of Health. Vaccinazione anti-SARS-CoV-2/COVID-19 PIANO STRATEGICO. <https://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2021&codLeg=78657&parte=1%20&serie=null>
- Task Force COVID-19 del Dipartimento Malattie Infettive e Servizio di Informatica. Istituto Superiore di Sanità. Epidemia COVID-19: Aggiornamento nazionale. [https://www.epicentro.iss.it/coronavirus/bollettino/Bollettino-sorveglianza-integrata-COVID-19\\_13-gennaio-2021.pdf](https://www.epicentro.iss.it/coronavirus/bollettino/Bollettino-sorveglianza-integrata-COVID-19_13-gennaio-2021.pdf) (2021).
- ISTAT-Istituto Nazionale di Statistica. <http://dati.istat.it/Index.aspx>
- GitHub. Covid-19 Opendata Vaccines. <https://github.com/italia/covid19-opendata-vaccini>
- Voltz, E. et al. Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: insights from linking epidemiological and genetic data. Preprint at *medRxiv* <https://doi.org/10.1101/2020.12.30.20249034> (2021).
- Moore, J. P. Approaches for optimal use of different COVID-19 vaccines. Issues of viral variants and vaccine efficacy. *JAMA* <https://doi.org/10.1001/jama.2021.3465> (2021).
- Davies, N. G. et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. *Science* <https://doi.org/10.1126/science.abg3055> (2021).
- Cousins, S. New Zealand eliminates COVID-19. *Lancet* **395**, 1474 (2020).
- Fouda, A., Mahmoudi, N., Moy, N. & Paolucci, F. The COVID-19 pandemic in Greece, Iceland, New Zealand, and Singapore: health policies and lessons learned. *Health Policy Technol.* **9**, 510–524 (2020).

### Acknowledgements

We acknowledge financial support through the Italian grant PRIN 2017 'Monitoring and Control Underpinning the Energy-Aware Factory of the Future: Novel Methodologies and Industrial Validation' (ID 2017YKXYXJ). This research has also received funding from the European Union's Horizon 2020 Research and Innovation Program 'PERISCOPE: Pan European Response to the Impacts of COvid-19 and future Pandemics and Epidemics' under grant agreement no. 101016233, H2020-SC1-PHE-CORONAVIRUS-2020-2-RTD.

### Author contributions

F.B., P.B., P.C., G.D.N. and G.G. proposed the model and performed the model fitting, simulations, analysis and interpretation of the results. R.B., M.C., A.D.F. and P.S. provided first-hand clinical insight and contextualization. All authors wrote and approved the manuscript.

### Competing interests

The authors declare no competing interests.

### Additional information


**Extended data** is available for this paper at <https://doi.org/10.1038/s41591-021-01334-5>.

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s41591-021-01334-5>.

**Correspondence and requests for materials** should be addressed to G.G.


**Peer review information** *Nature Medicine* thanks Tim Colbourn and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Jennifer Sargent was the primary editor on this article and managed its editorial process and peer review in collaboration with the rest of the editorial team.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).




**Extended Data Fig. 1 | Epidemic evolution in Italy from late February 2020 to March 2021.** Data (stars) and estimation (solid lines), based on the SIDARTHE model, of the time evolution of the epidemic, in logarithmic scale. Active cases (current diagnosed infected, related to the SIDARTHE variables  $R+T+D$ ) are shown in orange; hospital occupancy (related to the SIDARTHE variables  $R+T$ ) is shown in blue; ICU occupancy (related to variable  $T$ ) is shown in magenta; daily deaths (related to the derivative of variable  $E$ ) are shown in black.







**Extended Data Fig. 2 | Epidemic evolution without vaccination for different constant values of  $\mathcal{R}_0$ .** Time evolution of the epidemic, in the absence of vaccination, when different constant values of  $\mathcal{R}_0$ , namely  $\mathcal{R}_0 = 1.27$  (purple),  $\mathcal{R}_0 = 1.1$  (orange),  $\mathcal{R}_0 = 0.9$  (blue), are assumed, resulting from different variants and/or containment strategies. **a**, Time evolution of the fractions of susceptibles, infected and recovered, and dead. **b**, Daily new cases. **c**, Active cases. **d**, Hospital occupancy. **e**, ICU occupancy. **f**, Daily deaths.



**Extended Data Fig. 3 | Epidemic evolution without vaccination for different intermittent strategies.** Time evolution of the epidemic, in the absence of vaccination, when two alternative intermittent strategies are enforced, with an average value of  $\mathcal{R}_0$  equal to 1.1. The Open-Close strategy (red) switches every month between  $\mathcal{R}_0 = 1.27$  and  $\mathcal{R}_0 = 0.9$ , starting with  $\mathcal{R}_0 = 1.27$ . The Close-Open strategy (green) does the same, but starts with  $\mathcal{R}_0 = 0.9$ . **a**, Time evolution of the fractions of susceptibles, infected and recovered, and dead. **b**, Daily new cases. **c**, Active cases. **d**, Hospital occupancy. **e**, ICU occupancy. **f**, Daily deaths.




**Extended Data Fig. 4 | Effective vaccination schedules.** Profiles of the considered three different effective vaccination schedules: slow, medium and fast. For each of the three schedules, we show: the evolution over time of the daily effective vaccination rate, namely the fraction of population successfully immunised (second dose) in one day (a-d-g), the cumulative fraction of immunised population as a function of time (b-e-h), the resulting time-varying Case Fatality Rate as a function of time, obtained taking population age classes into account and assuming a vaccination schedule that prioritises the elderly (c-f-i).




**Extended Data Fig. 5 | Time-varying age-dependent Case Fatality Rate as a function of the vaccination schedule.** Computation of the time-varying Case Fatality Rate as a function of the vaccination roadmap, taking population age classes into account. **a**, Considered vaccination roadmap: fraction of non-vaccinated population over time. **b**, Cumulative Italian population as a function of age. **c**, Fraction of the population (red) and Case Fatality Rate (purple) as a function of age. **d**, Evolution of the overall Case Fatality Rate over time, assuming a vaccination schedule that gives priority to the elderly.






**Extended Data Fig. 6 | Epidemic evolution with adaptive vaccination for different constant values of  $\mathcal{R}_0$ .** Time evolution of the epidemic, with adaptive vaccination, when different constant values of  $\mathcal{R}_0$ , namely  $\mathcal{R}_0 = 1.27$  (purple),  $\mathcal{R}_0 = 1.1$  (orange),  $\mathcal{R}_0 = 0.9$  (blue), are assumed, associated with different variants and/or containment strategies. The adaptive vaccination speed is inversely proportional to the size of the epidemic, that is to the number of infection cases. **a**, Time evolution of the fractions of susceptibles, vaccinated, infected and recovered, and dead. **b**, Daily new cases. **c**, Active cases. **d**, Hospital occupancy. **e**, ICU occupancy. **f**, Daily deaths.





**Extended Data Fig. 8 | Health costs as a function of vaccination speed.** Health-cost vs. vaccination-speed curves: for a given  $\mathcal{R}_0$  profile, the curve gives the total ICU occupancy (a) and the total hospital occupancy (b) in the period from April 2021 to January 2022, as a function of the average vaccination speed, measured as the fraction of two-dose vaccinated population at the end of the period. The health-cost vs. vaccination-speed curves corresponding to a constant reproduction number are reported in purple ( $\mathcal{R}_0 = 1.27$ ), orange ( $\mathcal{R}_0 = 1.1$ ) and blue ( $\mathcal{R}_0 = 0.9$ ), while those corresponding to intermittent strategies are reported in red (Open-Close) and green (Close-Open).



**Extended Data Fig. 9 | Dynamic input-output models for health costs.** Estimation of the three dynamic input-output models linking new cases (input) to three outputs: deaths (**a**), hospital occupancy (**b**) and ICU occupancy (**c**). Each panel displays the observed outputs (grey) and the values predicted by the identified dynamic system (blue). In order to allow for weekly oscillations both input and output series were prefiltered with a 7-day moving average before performing nonlinear least squares fitting of a first-order model with delay. The FIT ratios of the three models are 83.16%, 84.67%, and 87.53%.



## Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided  
*Only common tests should be described solely by name; describe more complex techniques in the Methods section.*
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g.  $F$ ,  $t$ ,  $r$ ) with confidence intervals, effect sizes, degrees of freedom and  $P$  value noted  
*Give  $P$  values as exact values whenever suitable.*
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's  $d$ , Pearson's  $r$ ), indicating how they were calculated

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

### Software and code

Policy information about [availability of computer code](#)

Data collection

Data analysis

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research [guidelines for submitting code & software](#) for further information.

### Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

We gathered all epidemiological and demographic data from publicly available sources:

<https://github.com/pcm-dpc/COVID-19/tree/master/dati-andamento-nazionale>

[https://www.epicentro.iss.it/coronavirus/bollettino/Bollettino-sorveglianza-integrata-COVID-19\\_13-gennaio-2021.pdf](https://www.epicentro.iss.it/coronavirus/bollettino/Bollettino-sorveglianza-integrata-COVID-19_13-gennaio-2021.pdf)

<http://dati.istat.it/Index.aspx>

Data are also included in the Extended Data Figures 1 and 9, and in the code folder:

<https://giuliagiordano.dii.unitn.it/docs/papers/VaccineVariantsCode.zip>

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences       Behavioural & social sciences       Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	Not applicable. This is a mathematical modelling study and no in vitro/ in vivo experiments were conducted. Official data made publicly available by the Italian Ministry of Health were used.
Data exclusions	Official data made publicly available by the Italian Ministry of Health were used and no data were excluded from the analyses in our mathematical modelling study.
Replication	No in vitro/ in vivo experiments were conducted: official data made publicly available by the Italian Ministry of Health were used. The code is provided online by the authors and the findings are fully reproducible.
Randomization	Not applicable. This is a mathematical modelling study and no in vitro/ in vivo experiments were conducted. Official data made publicly available by the Italian Ministry of Health were used.
Blinding	Not applicable. This is a mathematical modelling study and no in vitro/ in vivo experiments were conducted. Official data made publicly available by the Italian Ministry of Health were used.

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

### Materials & experimental systems

### Methods

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> Antibodies
<input checked="" type="checkbox"/>	<input type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input checked="" type="checkbox"/>	<input type="checkbox"/> Animals and other organisms
<input checked="" type="checkbox"/>	<input type="checkbox"/> Human research participants
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input checked="" type="checkbox"/>	<input type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging